- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07309263
Srovnání účinků chytré aplikací podporovaného superpomalého joggingu a stacionární cyklistiky na respirační funkci a aerobní zdatnost u vysokoškolských studentů
Srovnání účinků chytré aplikací podporovaného super-pomalého joggingu a stacionární cyklistiky na respirační funkci a aerobní kondici u vysokoškolských studentů
As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, "super slow jogging" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Daliao
-
Kaohsiung City, Daliao, Tchaj-wan, 831301
- No. 151, Jinxue Rd.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- required no regular exercise training in the past six months
- ability to safely perform high-intensity cycling exercise
Exclusion Criteria:
- musculoskeletal limitations that prevented cycling exercise
- recent infection
- known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function
- smoking
- use of medications that may influence cardiopulmonary responses to exercise
- other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Super slow jogging
A smart app will provide pacing assistance, adjusting step frequency weekly: Week 1: 150 steps per minute Week 2: 180 steps per minute Week 3: 190 steps per minute Week 4: 200 steps per minute |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Experimentální: moderate exercise training
Continuous cycling training at moderate intensity of 60% VO₂max |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
|
Komparátor placeba: Control
not perform any exercise training |
This study is a randomized controlled trial employing simple randomization, where participants draw lots to assign groups. The experiment comprises three groups: the super-slow jogging group, the stationary bicycle group, and the control group. Both exercise intervention groups underwent 50-minute training sessions comprising a 10-minute warm-up, 30-minute main exercise, and 10-minute cool-down. Super-Slow Jogging Group: Utilized a smart app for pacing assistance, adjusting step frequency weekly: Week 1: 150 steps/minute Week 2: 180 steps/minute Week 3: 190 steps/minute Week 4: 200 steps/minute Stationary Cycling Group: Participants will engage in continuous cycling training at moderate intensity (60% VO₂max). Control Group: No exercise training intervention. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
VO2max (ml/kg/mL) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Age (yr) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
VEmax (L/min) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
AT% (%VO₂max) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Resting O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Max O₂ pulse (mL·beat-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
MIP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Cardiopulmonary Fitness
Časové okno: Before intervention and the end of intervention at 12 weeks
|
MEP (cmH2O) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Height (cm) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Weight (kg) |
Before intervention and the end of intervention at 12 weeks
|
|
Baseline anthropometric of the participants
Časové okno: Before intervention and the end of intervention at 12 weeks
|
BMI (kg/m²) |
Before intervention and the end of intervention at 12 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
FEV1 (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
FVC (L) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
FEV₁/FVC (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
FEF25-75% (L·s-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
PEF (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
MVV (L·min-¹) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Breathing reserve (%) |
Before intervention and the end of intervention at 12 weeks
|
|
Lung function
Časové okno: Before intervention and the end of intervention at 12 weeks
|
Dynamic Index (DI%) |
Before intervention and the end of intervention at 12 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- 114-0561
- 114-2813-C-242-003-B (Jiné číslo grantu/financování: National Science and Technology Council, Taiwan)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .